CSIMarket
 
Cormedix Inc   (CRMD)
Other Ticker:  
 
 
Price: $3.8000 $-0.01 -0.262%
Day's High: $3.88 Week Perf: 11.11 %
Day's Low: $ 3.64 30 Day Perf: 16.21 %
Volume (M): 448 52 Wk High: $ 6.09
Volume (M$): $ 1,701 52 Wk Avg: $3.94
Open: $3.82 52 Wk Low: $2.57



 Market Capitalization (Millions $) 215
 Shares Outstanding (Millions) 57
 Employees 17
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 0

Cormedix Inc
Cormedix Inc is a publicly traded pharmaceutical company based in Berkeley Heights, New Jersey, USA. The company was founded in 2006 by Dr. Ira Marks, a physician and medical researcher with over 25 years of clinical and drug development experience. Cormedix is dedicated to developing and commercializing innovative products for the prevention and treatment of infectious and inflammatory diseases.

Cormedix's flagship product is Neutrolin, a catheter lock solution designed to prevent catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. Neutrolin is a combination of three active ingredients: taurolidine, citrate, and heparin. Taurolidine is a broad-spectrum antimicrobial agent that kills bacteria, fungi, and viruses. Citrate is a potent anticoagulant that inhibits the formation of blood clots. Heparin is a common anticoagulant that prevents the formation of fibrin clots.

Neutrolin is currently undergoing phase 3 clinical trials in the USA and Europe. The results of the phase 2 trial were very positive, with a 70% reduction in CRBSIs compared to standard of care. The phase 3 trials are expected to be completed in 2021, and Cormedix plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) shortly thereafter. Neutrolin has received fast-track designation from the FDA, meaning that it will receive expedited review and approval.

Cormedix has a strong pipeline of other potential products, including a combination product for the treatment of diabetic foot infections and a taurolidine-based nasal spray for the prevention of COVID-19. The company has also developed a proprietary technology platform called the Hampden system, which uses microfluidics to simulate human physiology and disease. The Hampden system allows for rapid and cost-effective preclinical testing of new drug candidates.

Cormedix has a talented and experienced management team, including CEO Khoso Baluch, CFO Richard M. Cohen, and CMO Nahar Zaidi. The company has a market capitalization of approximately $135 million and is listed on the NASDAQ exchange under the ticker symbol CRMD. Cormedix has partnerships with several leading academic and research institutions, including the University of Toronto, the Mayo Clinic, and the University of California, San Francisco. The company is well-positioned to deliver innovative solutions to major unmet medical needs.


   Company Address: 300 Connell Drive Berkeley Heights 7922 NJ
   Company Phone Number: 517-9500   Stock Exchange / Ticker: NASDAQ CRMD
   CRMD is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

CorMedix Inc. Poised for Success: Commercial and Reimbursement Updates Accelerate DefenCath Launch

Published Tue, Jan 30 2024 1:30 PM UTC

In an exciting development, CorMedix Inc., a renowned biopharmaceutical company dedicated to combating life-threatening diseases and conditions, has recently unveiled significant updates concerning its business operations and the highly anticipated launch of its novel therapeutic product, DefenCath. This article aims to outline the facts surrounding these updates and assess ...

Management Announcement

DefenCath: Pioneering the Fight Against Life-Threatening Infections

Published Mon, Jan 8 2024 1:30 PM UTC

CorMedix Inc. Sets the Stage for Life-Saving Breakthrough with Commercial and Operational Updates
Berkeley Heights, N.J., Jan. 08, 2024 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company dedicated to developing and commercializing therapeutic products for preventing and treating life-threatening diseases and conditions, has recently divulged a series of commerc...

Partnership

CorMedix and Leapfrog Unite to Defend Patient Safety: A Milestone Partnership in Infection Prevention

Published Mon, Dec 4 2023 1:30 PM UTC

CorMedix Inc. Partners with The Leapfrog Group to Champion Patient Safety and Infection Prevention
CorMedix Inc., a leading biopharmaceutical company specializing in infectious disease treatments, has recently announced an exciting new partnership with The Leapfrog Group. As a member of Leapfrog?s prestigious Partners Advisory Committee, CorMedix will play a vital role i...

Cormedix Inc

Cormedix Inc's Innovative Medical Solutions Forge Ahead Despite Challenging Financial Results


Date:
Cormedix Inc, a leading pharmaceutical company specializing in the development of innovative medical solutions, reported financial results for the period ending September 30, 2023, leaving investors uncertain about its future performance.
During this period, Cormedix Inc experienced a loss of $-0.17 per share, which was on par with the previous year's figures. However, it is important to note that the company did show improvement from the previous reporting period, where the loss per share was $-0.25.

Cormedix Inc

Cormedix Inc Demonstrates Financial Resilience Despite Higher Shortfall in Q2 2023 Results; Maintains Stable Stock Performance Year-On-Year



Cormedix Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the second quarter of 2023. Despite experiencing a higher shortfall per share compared to the previous year and quarter, as well as decreased revenue, the company has shown resilience by maintaining stability in its stock performance and exhibiting a positive trend over the past five trading days.
I. Shortfall per Share
1. Second Quarter 2023:
- Cormedix Inc reported a shortfall per share of -$0.25, an increase from -$0.19 in the same quarter a year ago.
- Compared to the previous quarter, the shortfall per share grew marginally from -$0.24.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com